AI · SEMICONDUCTOR · FACT CHECK
SKD WIRETrue
The US Food and Drug Administration (FDA) has begun reviewing how to regulate generative AI in medical applications, according to information assessed as factual by primary sources.
The FDA, the US agency responsible for approving medical devices and drugs, is examining regulatory approaches for generative AI used in healthcare settings. The review concerns how the agency should evaluate and oversee generative medical AI products, which differ from traditional software in that their outputs can vary rather than follow fixed rules.
Generative medical AI sits at the intersection of two areas of strong Korean industry interest: large language models (LLM) and semiconductor demand, as medical AI workloads typically run on GPUs and other AI accelerators. A US regulatory framework would shape the market that Korean AI developers and hardware suppliers could serve.
The available information does not specify a timeline for the review or which FDA offices are leading the effort.
The claim that the FDA is reviewing regulation of generative medical AI is accurate. Verdict: True
